查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1961148

中轴型脊椎关节炎市场－全球产业规模、份额、趋势、机会、预测：按类型、药物类别、地区和竞争格局划分，2021-2031年

Axial Spondyloarthritis Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Drug Class, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 186 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球中轴型脊椎关节炎 (axSpA) 市场预计将从 2025 年的 60.8 亿美元成长到 2031 年的 83.1 亿美元，复合年增长率为 5.32%。

此领域涵盖频谱慢性发炎性风湿病，包括僵直性脊椎炎及其非放射性变异型，主要涉及脊椎和骶髂关节。市场成长的主要驱动力是自体免疫疾病盛行率的上升以及先进生物疗法（尤其是白细胞介素抑制剂）在临床上的应用日益广泛。此外，价格合理的生物相似药获得监管部门核准以及筛检措施的改进，使得患者更容易获得必要的治疗，从根本上推动了该行业的成长趋势。

市场概览
预测期 2027-2031
市场规模：2025年 60.8亿美元
市场规模：2031年 83.1亿美元
复合年增长率：2026-2031年 5.32%
成长最快的细分市场 非类固醇消炎剂（NSAIDs）
最大的市场 北美洲

儘管取得了这些进展，但临床诊断的显着延迟仍然是市场发展的主要障碍，阻碍了及时治疗性介入。低诊断效率限制了能够接受治疗的患者数量，并使长期疾病管理工作更加复杂。根据国际中轴型脊椎关节炎联盟（ASF）2024年的报告，全球患者从症状出现到正式确诊的平均延迟时间为7.4年。如此长的潜伏期是实现患者最佳治疗效果的重大障碍，也阻碍了市场充分发挥其渗透潜力。

市场驱动因素

新型IL-17抑制剂和JAK抑制剂的商业化正在从根本上改变中轴型脊椎关节炎的治疗格局，为对传统TNF抑制剂抗药性的患者提供标靶治疗。这些先进的药物疗法能够有效治疗放射学观察阳性和非放射学阳性的脊椎关节炎，从而有效扩大了目标患者群体，并迅速扩大了市场份额。此外，它们已被证实能够减轻发炎并预防脊椎结构损伤，这推动了其应用。例如，诺华公司在2024年10月发布的2024年第三季财报中宣布，其IL-17抑制剂Cosentyx的季度全球销售额达到17亿美元。此外，口服JAK抑制剂的使用也日益增多，与注射剂相比，口服JAK抑制剂具有更方便的给药方式。艾伯维公司2024年第三季财报显示，其Rinvoc的全球净销售额达到16.1亿美元，进一步显示了市场对这些创新作用机制的高度认可。

市场扩张的另一个驱动力是强大的下一代生物製剂临床研发管线，其中包括旨在实现更高缓解率的双重细胞激素抑制剂和奈米抗体。这些新型候选药物的不断涌现，创造了竞争激烈的市场环境，并透过改善治疗可及性和差异化的作用机制促进了成长。特别是，双重IL-17A/IL-17F抑制剂的出现，有望在临床试验中展现优于传统标准疗法的皮肤和关节症状改善效果。为了佐证这项快速普及，UCB于2024年7月发布的「2024财年上半年报告」显示，新上市的生物製药Bimzelx在上半年的净销售额达到2.15亿欧元，这充分展现了研发管线的活力，并将确保市场的长期可持续发展。

市场挑战

临床诊断的严重延误是限制全球中轴型脊椎关节炎 (axSpA) 市场商业性扩张的主要瓶颈。这种低下的诊断效率实际上将很大一部分目标患者群体限制在基层医疗和非风湿病诊疗机构，而这些机构通常不提供或不承保先进的生物製药疗法。因此，由于患者长期未接受治疗或仅接受特异性干预，製药公司面临目标市场规模显着缩小的挑战。由于这些患者进入风湿病专科诊疗路径的时间远晚于最佳时机，高价值疗法的获利能力受到直接限制，有效的早期疗育策略也常常被错失。

这种分散的转诊途径严重阻碍了市场渗透，造成了疾病高发生率与实际治疗启动之间的巨大差距。根据美国僵直性脊椎炎协会预测，到2024年，四分之一的患者需要咨询五位或更多医疗专业人员才能获得诊断。如此复杂的转诊途径降低了筛检效率，并延误了生物製剂治疗的启动。除非弥合这一转诊差距，否则市场将无法充分利用疾病的真实发病率，巨大的商业性价值也将无法充分挖掘。

市场趋势

将人工智慧增强型磁振造影技术应用于疾病早期检测，正成为全球中轴型脊椎关节炎（axSpA）市场的关键趋势。演算法被应用于扫描分析，能够自动识别常规检查中常被忽略的发炎标记物，从而缩短诊断时间。 UCB製药公司于2024年10月发表的一项题为「深度学习演算法效能分析」的研究报告指出，一种用于检测骶髂关节发炎的新型人工智慧模型与放射科专家的诊断结果完全一致，达到74%。此类创新对于提供标准化工具以区分axSpA和机械性腰痛，以及缩短治疗性介入时间至关重要。

同时，生物相似药TNF抑制剂的市场渗透率不断提高，正在重塑整个产业的竞争格局。医疗保健系统正在推动向这些更具成本效益的传统生物製药替代方案转变，从而有效提高了治疗的可及性。Adalimumab市场主导地位的削弱清晰地体现了这一变化，处方集的变化加速了销售量从原厂药物转移到生物相似药的情况。正如三星生物製剂公司于2024年10月发布的《2024年第四季美国生物相似药市场报告》中所述，Adalimumab生物相似药在美国的市占率从2024年初的2%成长到同年8月的22%。这一趋势迫使原厂药生产商在价格上竞争，同时也为新的治疗机制创造了资金空间。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：中轴型脊椎关节炎（axSpA）全球市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 依类型（僵直性脊椎炎（AS）、非放射性中轴型脊椎关节炎（nr-axSpA））
    • 药物分类（非类固醇消炎剂（NSAIDs）、糖皮质素、抗风湿药、其他）
    • 按地区
    • 按公司（2025 年）
  • 市场地图

第六章 北美中轴型脊椎关节炎（axSpA）市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国别分析
    • 我们
    • 加拿大
    • 墨西哥

第七章 欧洲中轴型脊椎关节炎（axSpA）市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国别分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太地区中轴型脊椎关节炎（axSpA）市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国别分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：中东和非洲轴性脊椎关节炎（axSpA）市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东与非洲：国别分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第十章：南美洲轴性脊椎关节炎（axSpA）市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国别分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 促进因素
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 近期趋势

第十三章 全球中轴型脊椎关节炎（axSpA）市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的议价能力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • UCB SA
  • Pfizer Inc.
  • Abbott Laboratories Inc.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • AbbVie Inc.
  • Novartis AG
  • Eli Lilly and Company
  • Amgen Inc.
  • GlaxoSmithKline plc
  • NorthStar Rx LLC

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 23171

The Global Axial Spondyloarthritis (axSpA) Market is projected to expand from USD 6.08 billion in 2025 to USD 8.31 billion by 2031, reflecting a compound annual growth rate of 5.32%. This sector encompasses a spectrum of chronic inflammatory rheumatic conditions, including ankylosing spondylitis and non-radiographic variants, which primarily impact the spine and sacroiliac joints. The growth of this market is largely fueled by the rising prevalence of autoimmune disorders and the increasing clinical adoption of advanced biologic therapies, particularly interleukin inhibitors. Additionally, the regulatory approval of affordable biosimilars and the implementation of enhanced screening initiatives are improving patient access to essential treatments, thereby fundamentally supporting the industry's upward trajectory.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 6.08 Billion
Market Size 2031USD 8.31 Billion
CAGR 2026-20315.32%
Fastest Growing SegmentNon-steroidal anti-inflammatory drugs (NSAID)
Largest MarketNorth America

Despite these advancements, the market faces a significant hurdle due to substantial delays in clinical identification, which hinder timely therapeutic intervention. This diagnostic inefficiency limits the accessible patient population and complicates long-term disease management efforts. In 2024, the Axial Spondyloarthritis International Federation reported that patients worldwide experienced an average delay of 7.4 years between the onset of symptoms and receiving a formal diagnosis. Such prolonged latency periods remain a critical barrier to achieving optimal patient outcomes and restrict the market from realizing its full penetration potential.

Market Driver

The commercialization of novel IL-17 and JAK inhibitor therapies is fundamentally reshaping the treatment landscape for axial spondyloarthritis by providing targeted efficacy for patients who are resistant to traditional TNF inhibitors. These advanced pharmacotherapies are rapidly gaining market share due to their ability to treat both radiographic and non-radiographic variants of the disease, effectively widening the eligible patient pool. Their adoption is further driven by a proven capability to reduce inflammation and prevent structural spinal damage; for instance, Novartis reported in its "Q3 2024 Financial Results" in October 2024 that global sales for the IL-17 inhibitor Cosentyx reached USD 1.7 billion for the quarter. Furthermore, the sector is seeing a shift toward oral JAK inhibitors, which offer administration convenience over injectables, with AbbVie's "Third-Quarter 2024 Financial Results" noting that global net revenues for Rinvoq hit USD 1.61 billion, underscoring the high value placed on these innovative mechanisms.

Market expansion is also being propelled by a robust clinical pipeline of next-generation biologics, including dual-cytokine inhibitors and nanobodies aimed at achieving deeper remission rates. This continuous influx of new candidates creates a competitive environment that improves treatment accessibility and stimulates growth through differentiated mechanisms of action. Notably, the emergence of dual IL-17A and IL-17F inhibitors has shown promise in clinical trials for delivering superior skin and joint clearance compared to earlier standards. Highlighting this rapid uptake, UCB's "Half-Year Report 2024" in July 2024 revealed that net sales for the recently launched biologic Bimzelx reached EUR 215 million in the first six months, demonstrating the vitality of a pipeline that ensures long-term market resilience.

Market Challenge

The significant latency in clinical diagnosis acts as a primary bottleneck that restricts the commercial expansion of the global axSpA market. This diagnostic inefficiency effectively isolates a large portion of the eligible patient population within primary care or non-rheumatological settings, where advanced biologic therapies are typically neither prescribed nor reimbursed. Consequently, pharmaceutical manufacturers encounter a considerably reduced addressable market, as patients remain untreated or are managed with non-specific interventions for extended periods. The revenue potential of high-value therapeutics is directly curtailed because these individuals enter the specialized rheumatology channel much later than optimal, often missing the window for effective early intervention strategies.

This fragmented referral pathway significantly hampers market penetration rates by creating a disconnect between the high prevalence of the disease and actual therapeutic adoption. According to the Spondylitis Association of America, in 2024, one in four patients consulted five or more healthcare professionals in search of a diagnosis. Such convoluted clinical journeys dilute the efficiency of screening initiatives and delay the initiation of biologic treatments. Until this referral gap is successfully bridged, the market will struggle to capitalize on the true prevalence of the disease, leaving a significant amount of commercial value unrealized.

Market Trends

The integration of AI-enhanced MRI for early disease detection is developing into a critical trend within the Global Axial Spondyloarthritis (axSpA) Market. Algorithms are now being utilized to analyze scans and automate the identification of inflammatory markers that are frequently missed during standard reviews, thereby countering diagnostic latency. A study by UCB Pharma in October 2024, titled "Performance analysis of a deep-learning algorithm," reported that a novel AI model for detecting sacroiliac joint inflammation achieved a 74% absolute agreement rate with expert readers. These innovations are pivotal for providing standardized tools to distinguish axSpA from mechanical back pain and for accelerating the timeline for therapeutic intervention.

Concurrently, the rising market penetration of biosimilar TNF inhibitors is restructuring competitive dynamics across the sector. Healthcare systems are increasingly incentivizing these cost-efficient alternatives to legacy biologics, which is effectively expanding treatment accessibility. This shift is highlighted by the erosion of market exclusivity for adalimumab, where formulary changes are driving volume transitions away from reference products. As noted by Samsung Bioepis in their "Fourth Quarter 2024 US Biosimilar Market Report" from October 2024, the market share for adalimumab biosimilars in the United States grew from 2% in early 2024 to 22% by August 2024. This trend forces originator manufacturers to compete on price while simultaneously opening fiscal space for newer therapeutic mechanisms.

Key Market Players

  • UCB S.A.
  • Pfizer Inc.
  • Abbott Laboratories Inc.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • AbbVie Inc.
  • Novartis AG
  • Eli Lilly and Company
  • Amgen Inc.
  • GlaxoSmithKline plc
  • NorthStar Rx LLC

Report Scope

In this report, the Global Axial Spondyloarthritis (axSpA) Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Axial Spondyloarthritis (axSpA) Market, By Type

  • Ankylosing spondylitis (AS)
  • Non- radiographic axial spondyloarthritis (nr-axSpA)

Axial Spondyloarthritis (axSpA) Market, By Drug Class

  • Non-steroidal anti-inflammatory drugs (NSAID)
  • Glucocorticoids
  • Anti-rheumatic drugs
  • Others

Axial Spondyloarthritis (axSpA) Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Axial Spondyloarthritis (axSpA) Market.

Available Customizations:

Global Axial Spondyloarthritis (axSpA) Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Axial Spondyloarthritis (axSpA) Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Ankylosing spondylitis (AS), Non- radiographic axial spondyloarthritis (nr-axSpA))
    • 5.2.2. By Drug Class (Non-steroidal anti-inflammatory drugs (NSAID), Glucocorticoids, Anti-rheumatic drugs, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Axial Spondyloarthritis (axSpA) Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Drug Class
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Axial Spondyloarthritis (axSpA) Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Drug Class
    • 6.3.2. Canada Axial Spondyloarthritis (axSpA) Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Drug Class
    • 6.3.3. Mexico Axial Spondyloarthritis (axSpA) Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Drug Class

7. Europe Axial Spondyloarthritis (axSpA) Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Drug Class
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Axial Spondyloarthritis (axSpA) Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Drug Class
    • 7.3.2. France Axial Spondyloarthritis (axSpA) Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Drug Class
    • 7.3.3. United Kingdom Axial Spondyloarthritis (axSpA) Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Drug Class
    • 7.3.4. Italy Axial Spondyloarthritis (axSpA) Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Drug Class
    • 7.3.5. Spain Axial Spondyloarthritis (axSpA) Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Drug Class

8. Asia Pacific Axial Spondyloarthritis (axSpA) Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Drug Class
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Axial Spondyloarthritis (axSpA) Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Drug Class
    • 8.3.2. India Axial Spondyloarthritis (axSpA) Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Drug Class
    • 8.3.3. Japan Axial Spondyloarthritis (axSpA) Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Drug Class
    • 8.3.4. South Korea Axial Spondyloarthritis (axSpA) Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Drug Class
    • 8.3.5. Australia Axial Spondyloarthritis (axSpA) Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Drug Class

9. Middle East & Africa Axial Spondyloarthritis (axSpA) Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Drug Class
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Axial Spondyloarthritis (axSpA) Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Drug Class
    • 9.3.2. UAE Axial Spondyloarthritis (axSpA) Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Drug Class
    • 9.3.3. South Africa Axial Spondyloarthritis (axSpA) Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Drug Class

10. South America Axial Spondyloarthritis (axSpA) Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Drug Class
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Axial Spondyloarthritis (axSpA) Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Drug Class
    • 10.3.2. Colombia Axial Spondyloarthritis (axSpA) Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Drug Class
    • 10.3.3. Argentina Axial Spondyloarthritis (axSpA) Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Drug Class

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Axial Spondyloarthritis (axSpA) Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. UCB S.A.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Pfizer Inc.
  • 15.3. Abbott Laboratories Inc.
  • 15.4. Johnson & Johnson
  • 15.5. Merck & Co., Inc.
  • 15.6. AbbVie Inc.
  • 15.7. Novartis AG
  • 15.8. Eli Lilly and Company
  • 15.9. Amgen Inc.
  • 15.10. GlaxoSmithKline plc
  • 15.11. NorthStar Rx LLC

16. Strategic Recommendations

17. About Us & Disclaimer